Abstract

UGT1A1 is the main metabolic enzyme for active product of Irinotecan (CPT-11).Its activity is closely related to the efficacy and adverse reactions of CPT-11.However,UGT1A1 * 28 gene polymorphism can significantly reduce the expression and activity of UGT1A1 enzyme.IP (irinotecan+cisplatin) program is the first-line chemotherapy of extensive stage small cell lung cancer,UGT1A1 * 28gene polymorphism may affect the efficacy and adverse reactions of IP program.So detecting UGT1A1 * 28gene polymorphism can guide individualized treatment of patients with small cell lung cancer. Key words: UGT1A1; Gene polymorphism; Small cell lung cancer; Irinoteca

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.